Go to the list of all blogs
Rick Johnson's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
Why Is SELLAS Life Sciences Group (SLS) Stock Up +164.12% Today?

Why Is SELLAS Life Sciences Group (SLS) Stock Up +164.12% Today?

Key Takeaways

  • SLS shares surged 164.12% to $19.73, a gain of $12.26 versus Monday's close of $7.47, in a high-volume session.
  • The primary catalyst is a clean pivotal win: the Phase 3 REGAL trial of galinpepimut-S met its primary overall-survival endpoint with statistical and clinical significance in acute myeloid leukemia.
  • Secondary drivers include a defined FDA filing path with a BLA targeted for the first half of 2027, plus broader pipeline optionality around tambiciclib (SLS009).
  • The move was entirely company-specific: small-cap biotech benchmarks drifted lower, with the sector operating as a headwind rather than a tailwind.
  • News Significance Score: 96/100 — Transformative pivotal data paired with a move roughly 37 times the stock's typical daily swing.
  • Traders are now watching the FDA meeting outcome, full REGAL secondary-endpoint disclosure, and December's SLS009 data at ASH 2026.
  • Investors can dig deeper into Price Targets, Earnings, and Forecast pages for detailed financial and valuation context.
  • For systematic, rules-based exposure to momentum names, explore Trending AI Robots.

Opening Summary

SELLAS Life Sciences Group, Inc. (SLS) is a late-stage clinical biopharmaceutical company developing novel cancer therapies, led by galinpepimut-S (GPS), an off-the-shelf immunotherapeutic cancer vaccine targeting the WT1 antigen, and tambiciclib (SLS009), a selective CDK9 inhibitor. The stock last traded at $19.73, up $12.26, or 164.12%, from the prior session's close of $7.47. The direction of the move is unambiguously higher, and the reason is not in dispute: before the opening bell, the company reported positive topline results from its pivotal Phase 3 REGAL trial, which met its primary endpoint and showed a survival benefit large enough to reset the entire investment case.

Phase 3 REGAL Data Deliver the Breakthrough

The REGAL trial tested GPS as maintenance monotherapy in patients with acute myeloid leukemia (AML) who reached a second or later complete remission after salvage therapy but who were ineligible for, or unable to undergo, an allogeneic stem cell transplant — a group with historically dismal outcomes and no approved standard of care.

The results cleared the bar decisively. GPS produced a median overall survival of 24.0 months versus 14.7 months for investigators' choice of best available treatment, a 41% reduction in the risk of death, with a hazard ratio of 0.59 and a two-sided p-value of 0.035. The safety profile was consistent with prior experience, with no new signals and mostly grade 1/2 local injection-site reactions. Critically, the vaccine beat physician-selected combination regimens as a single agent, which is the detail that drove the market reaction: it suggests the WT1-directed platform is validated at Phase 3, not merely tolerated.

Regulatory Path and Filing Timeline

Management said it will meet with the U.S. Food and Drug Administration to discuss an accelerated filing strategy, with preparations advancing toward a Biologics License Application submission for GPS in the first half of 2027. For a company with a modest revenue base and a development-stage profile, a credible, dated path to a first commercial approval is the single largest value inflection available, and it arrived ahead of expectations.

Pipeline Optionality Reinforces the Bid

The readout also sharpened the outlook for SLS009. Forty patients have enrolled in the Phase 2 study in newly diagnosed AML, with preliminary data expected before year-end, and additional relapse/refractory AML findings are slated for presentation at the American Society of Hematology meeting in December. Prior investigator-led work reported response rates in specific molecular subgroups. Bulls are now valuing two de-risked assets rather than a binary bet on one trial.

Market Context and Trading Activity

This was not a sympathy trade. The iShares Biotechnology ETF (IBB) slipped about 0.7% and the SPDR S&P Biotech ETF (XBI) eased 0.3%, while the broad market and small caps also traded modestly lower. SELLAS rose against all of them, which underlines the idiosyncratic nature of the move.

Volume was extraordinarily heavy, with turnover in the opening minutes already running at many multiples of the roughly four million shares the stock typically trades in a full session. Technically, the gap higher blew through the prior 52-week high near $15.88 and reclaimed every major moving average in a single session, reversing a downtrend that had taken the shares from $12.41 in mid-October to $7.47 on Monday. Such a violent re-rating leaves little nearby resistance from recent trading, but it also leaves a large unfilled gap behind.

News Significance Score

The score runs from 0, meaning no meaningful news and a move that is ordinary for the stock, to 100, meaning transformative news and an extreme, rare price move. This event scores 96 out of 100.

The verified news is about as material as it gets for a company of this size: a pivotal Phase 3 trial met its primary survival endpoint with statistical significance and set up a 2027 filing, an outcome that collapses years of clinical and financing risk. The price response was equally extreme — roughly 37 times the stock's average daily move over the past 79 sessions and larger than any of them, none of which exceeded 16%. Strong fundamentals and unusual trading combine into a near-maximum reading.

What Comes Next for SLS

The near-term agenda is regulatory and scientific. Investors will await details of the FDA meeting, the full REGAL dataset including secondary endpoints and subgroup analyses at an upcoming medical conference, and peer-reviewed publication. SLS009 remains the second catalyst: topline Phase 2 data in newly diagnosed AML are due before year-end, with ASH 2026 presentations in December.

Financially, the company ended September with $134.7 million in cash after a third-quarter net loss of $10.1 million, giving it runway into key milestones but also leaving it dependent on capital markets for a commercial launch build-out. Analyst coverage remains constructive, with at least one Buy rating and a target that today's price is closing in on — a reminder that the easy re-rating may already be partly captured. Risks include a narrower-than-hoped label, accelerated approval hurdles, dilution, and the tendency of catalyst-driven biotech rallies to retrace once the initial scramble fades.

Trending AI Robots

Tickeron's Trending AI Robots page curates the best-performing automated strategies under present market conditions, drawn from a library of hundreds of AI trading bots covering thousands of tickers. Each bot differs by strategy, timeframe, performance metrics, and the symbols it trades, so results vary widely across market regimes. The page surfaces only those currently standing out, making it a practical starting point for comparing approaches side by side. Visit the curated list to see which strategies are leading right now.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SLS

SLS's RSI Indicator reaching overbought territory

The RSI Oscillator for SLS moved into overbought territory on November 17, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

SLS broke above its upper Bollinger Band on November 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for SLS entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 60 cases where SLS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.

The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on SLS as a result. In 79 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.

The Moving Average Convergence Divergence (MACD) for SLS just turned positive on November 17, 2026. Looking at past instances where SLS's MACD turned positive, the stock continued to rise in 37 of 42 cases over the following month. The odds of a continued upward trend are 88%.

SLS moved above its 50-day moving average on November 17, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +8.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLS advanced for three days, in 240 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.352) is normal, around the industry mean (3.592). P/E Ratio (-38.273) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. SLS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 37 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -11%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 129%, while CUE experienced the biggest fall at -85%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was 10% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of biopharmaceuticals

Industry Biotechnology

Industry
Biotechnology
Address
7 Times Square
Phone
+1 646 200-5278
Employees
13
Web
https://www.sellaslifesciences.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.